Curcumin Alleviates Myocardial Ischaemia–Reperfusion Injury by Inhibiting NLRP3 Inflammasome Activation and Pyroptosis via the Nrf2/HO‐1 Pathway: An Integrated Network Pharmacology and Experimental Study
Basic & Clinical Pharmacology & Toxicology · 2026-06 · 138 (6)
DOI: 10.1111/bcpt.70232 ↗At a glance
Journal article in Basic & Clinical Pharmacology & Toxicology, published online on 2026-04-23. Written by Lingling Yao and 4 co-authors. Institution: Center for Coronary Artery Disease (CCAD), Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing Anzhen Hospital, Capital Medical Unive…. Major MEDLINE topics: NLR Family, Pyrin Domain-Containing 3 Protein, Myocardial Reperfusion Injury, Curcumin, Pyroptosis. 46 references. Funded by: Scientific Research Project of the Department of Education of Hubei Province.
Abstract (original language)
Objective
This study aims to screen potential targets of Curcumin (Cur) in Myocardial ischaemia–reperfusion injury (MIRI) using network pharmacology and molecular docking, and to experimentally validate whether Cur mitigates MIRI by modulating the NLRP3 inflammasome and pyroptosis via the Nrf2/HO‐1 pathway.
Methods
Potential Cur–MIRI targets were identified from public databases and analysed by topological algorithms; molecular docking assessed binding affinity. Cardioprotective effects were validated in vivo using a murine LAD ligation model (30 min ischaemia/24 h reperfusion) and in vitro using H9C2 cardiomyocytes subjected to hypoxia/reoxygenation (H/R). Cur was given as pretreatment. Mechanistic assays included tissue immunofluorescence, mtROS and JC‐1 staining, ELISA for cytokines, and Western blotting; Nrf2 was silenced by siRNA to test dependency.
Results
Network analysis revealed 481 common targets enriched in apoptosis, TNF and NOD‐like receptor pathways. Docking showed favourable binding to NLRP3 (−8.14 kcal/mol) and Nrf2 (−7.02 kcal/mol). In vivo Cur reduced myocardial injury markers, improved echocardiographic function, attenuated inflammation and mitochondrial ultrastructural damage, and decreased NLRP3/caspase‐1 expression. In vitro Cur lowered IL‐1β/IL‐18 and mtROS, preserved mitochondrial membrane potential, reduced apoptosis, upregulated Nrf2/HO‐1 and downregulated pyroptosis proteins (NLRP3, ASC, caspase‐1, GSDMD). Nrf2 silencing abolished these effects.
Conclusion
Combining in silico and experimental evidence, Cur attenuates MIRI by activating Nrf2/HO‐1 to inhibit NLRP3 inflammasome‐mediated pyroptosis.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Center for Coronary Artery Disease (CCAD), Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
- Department of Cardiology, Renmin Hospital, Hubei University of Medicine, Shiyan, China.
- Department of Hematology, Renmin Hospital, Hubei University of Medicine, Shiyan, China.
ORCID profiles: Jinghua Liu
Funding
- Scientific Research Project of the Department of Education of Hubei Province
Cite
APA
Yao, L., Qin, J., Shen, J., Zhang, F., & Liu, J. (2026). Curcumin Alleviates Myocardial Ischaemia–Reperfusion Injury by Inhibiting NLRP3 Inflammasome Activation and Pyroptosis via the Nrf2/HO‐1 Pathway: An Integrated Network Pharmacology and Experimental Study. Basic & Clinical Pharmacology & Toxicology, 138(6). https://doi.org/10.1111/bcpt.70232
Vancouver
Yao L, Qin J, Shen J, Zhang F, Liu J. Curcumin Alleviates Myocardial Ischaemia–Reperfusion Injury by Inhibiting NLRP3 Inflammasome Activation and Pyroptosis via the Nrf2/HO‐1 Pathway: An Integrated Network Pharmacology and Experimental Study. Basic & Clinical Pharmacology & Toxicology. 2026;138(6). doi:10.1111/bcpt.70232
BibTeX
@article{Yao2026,
author = {Yao, Lingling and Qin, Jun and Shen, Jun and Zhang, Fusheng and Liu, Jinghua},
title = {Curcumin Alleviates Myocardial Ischaemia–Reperfusion Injury by Inhibiting NLRP3 Inflammasome Activation and Pyroptosis via the Nrf2/HO‐1 Pathway: An Integrated Network Pharmacology and Experimental Study},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2026},
volume = {138},
number = {6},
doi = {10.1111/bcpt.70232}
}
EUVIMED